Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danavorexton - Takeda

Next Previous
Drug Profile

Danavorexton - Takeda

Alternative Names: TAK-925

Latest Information Update: 25 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Cyclohexanes; Esters; Ethers; Piperidines; Sleep disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Orexin receptor type 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiration disorders
  • Phase I Narcolepsy
  • No development reported Idiopathic hypersomnia
  • Discontinued Neurological disorders; Sleep apnoea syndrome

Most Recent Events

  • 25 Sep 2025 Discontinued - Phase-I for Sleep apnoea syndrome (In the elderly, In adults) in Australia (IV) (Takeda Pipeline, September 2025)
  • 25 Sep 2025 Discontinued - Phase-II for Sleep apnoea syndrome in USA (IV) (Takeda Pipeline, September 2025)
  • 18 Sep 2025 Danavorexton is still in phase I development in Narcolepsy (In volunteers) in USA (IV, Infusion) (Takeda pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top